Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 14/20 | 0.58 |
| ▸ | EED | O75530 | 13/20 | 0.57 |
| ▸ | RBBP4 | Q09028 | 13/20 | 0.57 |
| ▸ | SUZ12 | Q15022 | 13/20 | 0.57 |
| ▸ | AEBP2 | Q6ZN18 | 13/20 | 0.57 |
| ▸ | EZH1 | Q92800 | 12/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20718752 | 0.92 | EZH2 (0.60) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20718769 | 0.90 | EZH2 (0.61) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20727203 | 0.85 | EZH2 (0.58) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20727148 | 0.84 | EZH2 (0.68) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20718767 | 0.83 | EZH2 (0.63) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20718770 | 0.83 | EZH2 (0.62) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20718756 | 0.82 | EZH2 (0.66) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20727195 | 0.80 | EZH2 (0.63) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20718761 | 0.80 | EZH2 (0.56) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20727143 | 0.80 | EZH2 (0.62) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108699029-B | 4,5, 6-trisubstituted indazole derivatives, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20200262812-A1 | 4, 5, 6-TRI-SUBSTITUTED INDAZOLES DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN MEDICINES | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-08-20 | — | — | US | disclosed |
| US-20200262812-A1 | 4, 5, 6-TRI-SUBSTITUTED INDAZOLES DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN MEDICINES | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-08-20 | — | — | US | disclosed |
| EP-3441388-A1 | 4,5,6-TRI-SUBSTITUTED INDAZOLES DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2019-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262812-A1 | 4, 5, 6-TRI-SUBSTITUTED INDAZOLES DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN MEDICINES | CYP3A4, CYP4B1, CYP3A7 | EZH2 1830/4885EED 4737/4885RBBP4 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.